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2 Background: Hydrocephalus is managed by surgically implanting flow-diversion 
technologies such as differential pressure valves and anti-siphoning devices, however, such 
hardware is prone to failure. Extensive research has tested them in flow-controlled settings 
using saline or deaerated water, yet little has been done to validate their performance in a 
setting recreating physiologically-relevant parameters including intracranial pressures, CSF 
protein content, and body-position. 
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Objective: In order to more accurately chart the episodic drainage characteristics of flow9 
diversion technology, a gravity-driven benchtop model of flow was designed and tested 
continuously during weeks-long trials. 
Methods: Using a hydrostatic pressure gradient as the sole driving force, interval flow-rates 
of six valves were examined in parallel with various fluids. Daily trials in the upright and 
supine positions were run with fluid output collected from distal catheters placed at 
alternating heights for extended intervals. 
Results: Significant variability in flow-rates was observed, both within specific individual 
valves across different trials and among multiple valves of the same type. This inter-valve 
and intravalve variability was greatest during supine trials and with increased protein. None 
of the valves showed evidence of overt obstruction during 30-days of exposure to 
cerebrospinal fluid containing 5g/L protein. 
Conclusions: Day-to-day variability of ball-in-cone differential pressure shunt valves may 
increase overdrainage risk. Narrow-lumen high-resistance flow control devices as tested here 
under similar conditions appear to achieve more consistent flow-rates suggesting their use 
may be advantageous, and did not demonstrate any blockage or trend of decreasing flow over 
the three weeks of chronic use. 
 
Introduction 
Ventriculoperitoneal shunts (VPSs) are used widely in the surgical management of 
hydrocephalus1-14. While these interventions can be lifesaving, possible complications 
include infection, obstruction, and overdrainage5-8,13-19. Overdrainage in particular can be a 
major contributor to patient morbidity, and understanding how vulnerable or resilient 
commonly-used devices may be to overdrainage is critically important to the neurosurgeon. 
While previous studies characterized the effect of proteins on CSF flow dynamics in fixed 
differential-pressure valves (DPVs), the effects of protein on the behavior of more complex 
shunt systems remain largely unknown16,20. Shunt technology has evolved over the past years 
with the advent of programmable valves. Many of these are DPVs gated by mechanisms such 
as ball-in-cone systems, the opening pressure of which is modulated by increasing or 
decreasing tension exerted upon it by an adjustable spring. These features enable clinicians to 
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calibrate a valve’s opening pressure to meet their patients’ drainage needs. However, such 
adjustments cannot independently compensate for the wide fluctuations of relative pressures 
that may occur daily, secondary to simple changes in body position and activity. Despite the 
advent of anti-siphon devices (ASDs), overdrainage remains a common concern for 
neurosurgeons, and the effects of protein content on CSF flow through such dynamic devices 
remains underinvestigated. 
To more realistically evaluate flow characteristics through a variety of CSF-diversion devices 
a gravity-driven benchtop model was developed for the functional assessment of flow-rates 
over consecutive trials conducted for several weeks. Previous testing systems have utilized 
steady flow pumps to achieve and maintain target flow-rates, and in doing so may generate 
unrealistically high pressures unlikely to be seen in the living system15,20-28. In contrast, our 
testbed was developed to maximize similarity to in vivo shunting, operating within the range 
of physiologic pressure parameters by utilizing gravity as the main driving force for drainage. 
This system also accommodates episodic alterations in distal catheter position to mimic 
position changes and consequent pressure differentials seen in ambulatory patients. 
Furthermore, we used this system to test CSF flow using pathological fluids, evaluating post-
hemorrhagic, high-protein CSF (with cellular material removed) to better understand flow 
dynamics of shunting under these conditions. Here, we demonstrate trends in the flow of 
normal and pathological fluid through a unique in vitro shunt evaluation system, providing 
some insight into the inner workings of these variable systems. 
 
Materials and Methods 
System 
The testing system consisted of a common “ventricle” situated within a tissue-culture 
incubator (Thermo Fisher Scientific) set to 37˚C, 100% humidity, and atmospheric 
conditions, atop an orbital shaker (Troemner) to prevent sedimentation (Figure 1). On the 
ventricle’s base were ports that allowed for continuous refilling, attachment of a manometer, 
and entry for six separate proximal catheters (Supplemental Methods). For all trials, three 
Codman Hakim® ball valves (HBVs) and three Certas® Plus ball valves (CPBVs) (Codman 
by Integra) were tested in parallel. 
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New valves and catheters were provided from the manufacturer with integrated 
SiphonGuard® (SG) ASDs (Codman by Integra). The ventricle was continuously refilled by 
reservoir flasks (Corning) situated above the ventricle. This height differential determined the 
hydrostatic potential driving fluid through the shunt systems. 
Valves were connected to Bactiseal® catheters (Codman by Integra), reinforced with 
ligatures, and submerged underwater to prevent air entry. The distal catheters emptied into 
collecting flasks which were placed 2cm- or 28.5cm-below the height of the valves to 
recreate different position-dependent flow-rates seen in the horizontal (supine) and vertical 
(upright) states, respectively. Every 24-hour period consisted of a 6-8 hour supine trial and a 
12-15 hour upright trial. At the conclusion of each trial, the total fluid output was weighed 
and the average flow rates were calculated for each valve. Groups of contiguous sets of trials 
extended over at least three weeks with different fluids. 
 
Fluids 
The system was designed to run a variety of fluids mimicking different physiological and 
pathological states. It was calibrated using both normal saline (Hospira) and saline containing 
1g/L of Bovine Serum Albumin (BSA, Sigma Aldrich). 1g/l of BSA was chosen as it 
represents a pathologically elevated level of the specific protein found to be the major 
component of protein deposition detected in recovered catheters29. To further challenge the 
hardware under more extreme conditions, human CSF with protein elevated beyond the 
normal pathological range was used in additional trials. CSF was collected from 87 patients 
at our institution with intraventricular hemorrhage following IRB approval and informed 
consent. CSF samples were combined, forming an aggregate with a protein concentration of 
1.63g/L, and BSA was added to a final concentration of 5g/L. CSF was centrifuged to 
remove blood and cellular material. The supernatant was filtered, and amphotericin B (Sigma 
Aldrich), penicillin/streptomycin (Gibco), and chlorhexidine dihydrochloride (Sigma 
Aldrich) were added to minimize risk of contamination. Protein was measured throughout the 
trial to ensure that concentration remained stable. 
 
Results 
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Continuous trials of six programmable ball-in-cone valves exposed to physiologic pressures 
were carried out over a minimum two-week duration for system validation and calibration of 
resistance settings. The goal of validation was to determine if the valve flow-rates varied 
independently or uniformly between trials. Low-resistance saline trials were run with three 
CPBVs maintained at a low-resistance setting of 2 and three HBVs at an equivalent setting of 
50. Valves were subsequently tested under medium-resistance settings (CPBV:4, HBV:100) 
for 27 days (Figure 2). Regular-interval measurements over the course of each daytime trial 
confirmed that flow-rates remained constant and independent for each valve. As the system 
ran, ICP level depreciated linearly with time, however this trend was minimal and did not 
appear to influence interval flow rates in either state. 
 
Saline, Low-resistance 
The mean flow-rates of saline through CPBVs and HBVs with valves at low-resistance 
settings in the supine position were 31.0ml/h (SD 5.2) and 35.2ml/h (SD 6.5), respectively. 
During upright-position trials in otherwise identical conditions, mean flow-rates were 
27.4ml/h (SD 0.76) and 22.5ml/h (SD 1.23) through the same respective valves (Table 1). 
 
Saline, Medium resistance 
When valve opening pressures were readjusted to medium-resistance settings, mean flow-
rates in the upright position decreased only slightly compared to those with low-resistance 
settings for both types of valves (CPBV: 21.29ml/h, SD 1.56; HBV: 20.23ml/h, SD 1.84). In 
contrast, the mean flow-rates in the supine position slowed dramatically to 0.05ml/h and 
0.06ml/h (SD 0.08 and 0.09) for CPBVs and HBVs, respectively. For all subsequent trials 
testing saline with protein, medium-resistance settings were maintained throughout. 
 
Saline + BSA (1g/L) 
In the supine position, mean flow-rate with saline containing 1g/L of BSA through CPBVs 
was 3.23ml/h (SD 4.54). Their mean flow-rate in the upright position was 22.1ml/h (SD 1.72) 
over alternating trials within the same time period. 
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Similarly, HBVs drained an average of 0.22ml/h (SD 0.76) in the supine position and 
20.12ml/h (SD 2.75) when upright. An increase in variability was noted, as evidenced by the 
greater SD values compared to normal saline trials. 
 
CSF + Protein (5g/L) 
A total of 35 trials with 5g/L BSA CSF were run over 18-days throughout a 30-day period in 
which the valves were continuously exposed to the fluid. For the final 22 trials, all valves 
were maintained in their respective medium-resistance settings. At these settings, CPBVs 
recorded a mean flow-rate of 11.85ml/h (SD 7.67) in the supine position and 21.78ml/h (SD 
3.94) in the upright position among 12 and 10 trials, respectively. HBV performance during 
the same trials achieved mean flow-rates of 10.74ml/h (SD 6.88) and 18.97ml/h (SD 1.68) in 
their respective supine and upright positions. 
 
Device performance over time 
None of the CPBVs, HBVs, or their integrated SGs showed any signs of overt failure or 
downward trend in flow-rates related to progressive occlusion over the duration of these trials 
(Supplementary Table 1). 
 
Discussion 
In this study, two types of differential pressure ball-in-cone valves were tested over 
prolonged intervals in a novel gravity-driven testing apparatus. Increased flow and variability 
were found after the addition of protein, across all valve types and positional states. These 
changes were observed using a testbed specifically designed for assessing performance of 
devices within physiologically relevant conditions. 149 Although both valve types are 
manufactured by the same company, their different ball-in-cone mechanisms, in conjunction 
with and without an additional high-resistance pathway represent a broad range of devices 
used today. 
In contrast to models utilizing steady-flow pressure pumps, the use of a hydrostatic pressure 
gradient calibrated to physiologic parameters provided a platform to accurately sense changes 
in flow secondary to variations in head position and protein concentration16-18,20,22,23. Normal 
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diurnal positional changes were mimicked by raising and lowering the distal catheter height 
relative to the valves. Various ASDs have been designed that respond to a surge or siphoning 
of fluid by dampening the immediate CSF outflow. Combining programmable valves with 
ASDs allows the primary device to further respond to sudden positional changes. 
Nevertheless, concerns over the long-term performance of DPVs and ASDs both alone and in 
series are still debated. SG, a secondary mechanism designed to divert a surge of fluid along 
a narrower, higher-resistance pathway, provided flow regulation in response to these 
positional changes25,28,30. 
To provide insight into the real-world behavior and interactions between DPVs and ASDs, 
specific valves with integrated SG were chosen. When disengaged, the SG’s suspended 
ruby ball allows unobstructed flow from the DPV through the primary outflow path. When a 
greater hydrostatic differential across the system forces the SG’s ruby ball to engage, this 
primary path is blocked and flow is diverted through a narrower lumen pathway which by 
increased resistance consequently reduces flow. These hardware selections allowed the study 
of fluid output across alternating flow states within the same device. 
Having all six of the tested valves connected to the same fluid chamber (ventricular 
representation) allowed uniform control of ICP changes, temperature, and fluid composition. 
Other variables such as ICP, ventricle volume, and CSF cellularity were held constant or 
eliminated from this model to reduce confounding factors. 
A range of biologically relevant fluids were used in order to better simulate the 
intraventricular environment and theoretically increase the system’s sensitivity to 
hardware obstruction due to protein compared to water-filled rigs15,21-23. To challenge 
these devices, they were tested using post-hemorrhagic CSF with added protein to observe 
how the hardware might handle exposure to high protein concentration over time. This 
realistic, independent testing of VP shunt hardware is critical for assuring the safety and 
reliability 179 of CSF flow-diversion technologies widely used to manage adult and pediatric 
hydrocephalus15,20-23,25,27. 
 
Effects of Protein on Mean Flow-rate 
Previous studies by Brydon et al. on PS Medical Flow Control and Cordis-Hakim valves 
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demonstrated that the addition of protein decreases opening and closing pressures16,20. We 
further investigated these variables on the performance of two commonly used, newer 
generation valves in a long-term setting and within the context of positional changes using 
both saline and protein-augmented CSF. Our findings are consistent with Brydon’s studies, 
demonstrating a trend towards increased flow rates with the addition of protein. Specifically, 
when tested over 30-days, trials of valves in the supine position showed higher flow-rates 
with 1g/L BSA in normal saline, compared to normal saline (Figure 3). While data reflected a 
statistically significant trend in all CPBVs (p<0.0001), significance was not reached in any of 
the HBVs (Figure 3). 
During upright trials over the same time interval, flow-rates in the CPBVs were consistently 
higher with the addition of 1g/L BSA compared to normal saline (p<0.001). In the upright 
position, two HBVs showed significant increases in flow-rates with BSA compared to saline 
(p<0.02, p<0.0001), however a slower mean flow-rate was recorded in one valve (p<0.0001). 
When patient-derived CSF was introduced, markedly increased rates were recorded in the 
supine position (p<0.0001 for all six valves) compared to saline both with and without BSA. 
Interestingly, in the upright position, no pattern of flow-rate changes were found compared 
with other fluids (Figure 3). These observations suggest that the effect of protein on increased 
flow is dependent upon the ball-in-cone mechanism, as these flow-rate increases are lost 
when the ASD engages and diverts fluid through the narrow high-resistance pathway. 
 
Variability Among and Within Valves at Baseline 
During the saline calibration trials it became clear that each of the valves tested had its own 
set point. These values all fell within the parameters described in the product safety literature. 
Longitudinal flow-rates for each valve varied slightly but showed no directional trend 
(Supplemental Figures 1-9). 
 
Effects of protein on differential pressure and high-resistance valves. 
Previous experiments have examined CSF shunt hardware using a narrow scope of fluids, 
which limits the generalizability of these results regarding the performance of such devices. 
In particular, ISO standards for medical devices only require testing with distilled water, 
Supplemental Digital Content SupFig10 Click here to access/download;Supplemental Digital Content (for 









which may misrepresent flow in the biological setting. Our studies sought to incorporate 
factors that more realistically represent and challenge the working environment of flow 
diversion hardware in normal and pathological states. With the introduction of these 
variables, a number of observations were noted. For example, in supine position trials, 
addition of protein resulted in increased range and variation of flow-rates (Supplemental 
Figure 10). These findings were amplified in 5g/L protein-CSF compared to 1g/L BSA 
saline, suggesting a dose responsiveness of protein content with shunt flow-rate variance. In 
concordance with previous studies16, we hypothesize that this increase in variability could be 
the result of a slower activation of the ball-in-cone mechanism due to increased adhesive 
properties of protein in solution. Possible explanations for these observations may be related 
to rheological factors affected by the increased protein concentration, namely a potential 
influence on viscosity, surface tension, and binding to the DPV’s internal components. The 
fact that these changes in SD and range were not seen in upright trials may indicate that SG's 
high-resistance pathway might be less prone to protein-induced effects. Clinical concerns 
have been raised regarding the reliability and risk of obstruction of shunting devices with 
narrow pathways. In order to explore the limits of these shunting devices, we tested 
supraphysiologic protein levels flowing continuously over prolonged intervals in a virtually 
sterile environment. This setup was designed to allow greater sensitivity to gradual decreases 
in flow and acute valve failures, excluding blockages secondary to air bubble formation, fluid 
contamination, and protein sedimentation. Furthermore, the use of filtered CSF avoided shunt 
blockages due to blood product accumulation, a well-known and previously investigated 
etiology of shunt failure16,20. To the best of our knowledge, these studies represent the longest 
continuously running model of shunt flow using a non-pump-driven system. 
Although no obstructions or flow decreases were detected, it must be noted that even trials 
lasting several weeks represent only a snapshot of these systems’ intended lifespans in 
patients. 
 
 Clinical Significance. We designed our valve testing apparatus to operate within physiologic 
parameters. Our findings are consistent with previous evidence showing that shunt valves 
with ASDs perform reliably in the upright position over long periods of time with 
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nonparticulate fluids28,30. The use of high protein CSF resulted in significantly increased 
supine flow-rates compared to normal saline. An 8-hour supine period combined with 14 
hours in the upright position with 1g/l of BSA resulted in average increases of 36.8ml, 
translating to a total daily fluid output of 335.3ml, which may lead to overdrainage in certain 
situations. These results suggest that protein content can have an important influence on 
shunt flow-rates, and might be of particular consideration when managing valve settings in 
patients predisposed to increased CSF protein. However, the effects of protein on fluid output 
across a prolonged series of trials indicates that these effects are somewhat variable. In the 
supine position, for example, the range of flow-rates in saline (low-resistance settings), saline 
with 1g/l BSA, and 5g/l protein-CSF varied dramatically when compared to similar upright 
trials. One particular CPBV demonstrated supine outputs ranging from 8.0ml (flow-rate 
0.96ml/h) to 123.84ml (flow-rate 15.48ml/h) with low protein. This pattern was seen in all 
valves (CPBV and HBV) and was independent from external variables such as temperature, 
ICP, valve setting/position. This variability in supine flow-rates might be clinically relevant, 
leading to higher uncertainty with regards to the actual volume drained by their shunts, 
especially among those who are bedridden. 
These findings, although preliminary, suggest that the engagement of SG’s narrow path 
confers less flow-rate variation in response to the challenges of elevated protein. These 
results may reinvigorate arguments favoring the use of a long, high-resistance pathway as 
means of tighter regulation of CSF-diverting flow, though further studies are warranted. 
 
Limitations 
Our attempt to recreate physiologic parameters of CSF flow is not without limitations. While 
this in vitro model of shunting using gravity-driven flow controlled for many variables, there 
is no doubt that it oversimplifies in vivo shunting by not taking into account multiple daily 
positional changes and features such as CSF pulse pressure, cardiorespiratory variations, 
abdominal backpressure, and CSF absorption. Importantly, we recognize that even the 
extended duration of these benchtop trials is nevertheless eclipsed by the intended lifespan of 
these devices in vivo. Lastly, while the valves studied were chosen due to their mechanistic 
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Here, we created a novel benchtop model of VP shunting with gravity-driven flow, allowing 
for parallel testing of multiple shunts at near-physiologic experimental conditions. Using this 
model, we examined the effects of both diurnal positional change and protein concentration 
on shunt flow in two commonly used DPVs with high-resistance ASDs. These studies 
showed no protein dependent flow obstruction on any valve system, including the narrow 
high-resistance pathway. 
While these studies provide some of the longest continuously collected data from a 
realistically flowing system with high-protein CSF, the test durations do not approach the 
intended lifespan of these devices, limiting one’s ability to conclusively comment on their 
long-term resistance to protein-related occlusion in long-term chronic use. Significant 
variability was demonstrated in ball-in-cone DPVs. The addition of protein resulted in higher 
flow in the supine trials, whereas engagement of the high-resistance pathway in upright trials 
provided more consistent performance in that position. Furthermore, attenuation of protein-
related increases in day-to-day variability by narrow-lumen devices suggests they may play 
an important role in preventing overdrainage. 
These findings suggest that clinically significant changes in flow-rates in DPVs may increase 
with highly elevated protein levels, and that this variability is potentially attenuated by 
activating a narrow-lumen high-resistance pathway as used with SG. While questions remain 
about possible risks of overdrainage using unvalved pathways alone, and about possible 
longer-term blockage of narrow pathways, this study suggests that further exploration of 
alternatives to ball-in-cone differential pressure valves is warranted. 
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Figure 1: Illustration of the Bench-top Shunt Model with a Comparative Schematic. 
Reservoir units (A) provide a hydrostatic driving force that keeps the central ventricle unit 
(B) filled with fluid as it drains through proximal catheters (C) that penetrate the bottom of 
the unit. This driving force can be adjusted to mimic intracranial pressure (ICP) by 
controlling the height differential between the reservoir units on the top shelf and the valves 
(D) below. Fluid that flows through the valves passes through distal catheters (E) which 
empty into their respective measuring flasks which can be positioned 28.5 or 2 cm below the 
height of the valves in order to recreate the patient’s upright (F) or supine (G) position 
states. 
 
Table 1: Average flow-rates and standard deviations of each individual CPBV (A, C) and 
HBV (B, D) for all trials in the supine (A, B) and upright (C, D) states. 
 
Figure 2: Daily average flow-rates grouped by valve type in the supine (solid) and upright 
384 (dashed) positions for saline without (A, B) and with protein (C), and CSF with protein 
(D). No downward trends in flow-rates were noticed over time. For supine trials with saline, 
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flow-rates decreased when resistance settings were increased from low to medium. Supine 
flow-rates subsequently rose with the addition of BSA and furthermore CSF with BSA. 
 
Figure 3: Scatter plot of every individual flow-rate measured in the (A) upright and (B) 
supine positions for all three CPBVs and HBVs over the duration of all trials, separated by 
study fluid. Each dot represents a single trial, with each of the three distinct CPBVs 
represented by shades of blue and each of the three HBVs shown as shades of red. The 
narrow clustering of each distinct valve’s upright flow-rates in saline (with and without 
protein) is lost in the upright CSF+Protein trials. 
 
 
Supplemental Digital Content. Table 1. Statistical analysis of variance (ANOVA) among 
sets of valves according to different positional states and fluids. Repeated measures ANOVA 
showed no significant downward or upward trend in CPBVs and HBVs valves during trials 
with 400 normal saline, normal saline + BSA 1 g/l and CSF + 5 g/l.  
Supplemental Digital Content. Figure 1-2. Consecutive Trial Flow Rates of all CPBVs and 
HBVs in Saline. A combined total of 55 supine and upright trials of three CPBVs (1) and 
three HBVs (2) valves in saline were alternatingly tested for 6- and 14-hour periods, 
respectively, over a span of 28 days. Average flow rates are given in ml/h for each individual 
trial. Upright trials 
are represented by lines connecting open circles (white areas), and supine trials by lines 
connecting filled circles (shaded areas). Horizontal axis depicts both cumulative hours (grey 
labels) and day numbers (black labels). All CPBVs and HBVs were maintained at settings of 
4 and 50, respectively. 
 
Supplemental Digital Content. Figure 3. Saline - Consecutive average flow rates by trial 
alternating supine and upright flow states in CPBVs (red line) and HBVs (blue line). 
 
Supplemental Digital Content. Figure 4-5. Consecutive Trial Flow Rates of all BPBVs and 
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HBVs in Saline + 1 g/l BSA. Thirty three trials testing three CPBVs (4) and three HBVs (5) 
in saline with 1g/l BSA were alternatingly tested in the supine and upright positions for 6- 
and 14-hour periods, respectively, over a span of 23 days. Average flow rates are given in 
ml/h for each individual trial. Upright trials are represented by lines connecting open circles 
(white areas), and supine trials by lines connecting filled circles (shaded areas). Horizontal 
axis depicts both cumulative hours (grey labels) and day numbers (black labels). All CPBVs 
and HBVs were maintained at settings of 4 and 50, respectively. 
 
Supplemental Digital Content. Figure 6. Saline + 1 g/l B - Consecutive average flow rates by 
trial alternating supine and upright flow states in CPBVs (red line) and HBVs (blue line). 
 
Supplemental Digital Content. Figure 7-8. Consecutive Trial Flow Rates of all CPBVs and 
HBVs in CSF + 5g/l Protein. Thirty five trials of three CPBVs (7) and three HBVs (8) in CSF 
with 5g/l of protein were alternatingly tested in the supine and upright positions for 6- and 
14-hour periods, respectively, over a span of 30 days. Average flow rates are given in ml/h 
for each individual trial. Upright trials are represented by lines connecting open circles (white 
areas), and supine trials by lines connecting filled circles (shaded areas). Horizontal axis 
depicts both cumulative hours (grey labels) and day numbers (black labels). Different valve 
settings were used throughout the trial, as indicated by the blue arrow bars under the 
horizontal axis. 
 
Supplemental Digital Content. Figure 9. CSF + protein (5g/L) - Consecutive average flow 
rates by trial alternating supine and upright flow states in CPBVs (red line) and HBVs (blue 
line). 
 
Supplemental Digital Content. Figure 10. Individual flow rates by trial and fluid (saline – 
black dots, saline + protein 1g/l - red dots, CSF + protein 5 g/l - blue dots) in supine and 
upright states in CPBVs and HBVs. 
 
Supplemental Digital Content. Materials and Methods. 
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Supplemental Digital Content. Materials and Methods 
System 
The shunt flow testing system consisted of a common central water-tight “ventricle” placed 
upon the middle shelf of a tissue culture incubator (Thermo Fischer Scientific, Waltham, 
MA) maintained at 37˚C, 100% humidity, and atmospheric CO2 and pressure (Figure 1). 
The ventricle was housed on the middle shelf of the incubator atop an orbital shaker to 
prevent sedimentation (Troemner, Thorofare, NJ). Affixed to the ventricle’s base were 
twelve luer-style adapter ports (Qosina, Ronkonkoma, NY). Six of these ports housed 
separate proximal catheters, to allow for simultaneous flow measurement in six complete 
shunts (proximal catheter, valve, distal catheter) in parallel. For all flow trials, three Codman 
Hakim® ball valves (HBVs) and three Codman Certas® Plus ball valves (CPBVs) were tested 
in parallel. All valves and catheters were new, provided directly from the manufacturer 
(Codman by Integra, Plainsboro, NJ) and contained integrated SiphonGuard® (SG) anti-
siphoning devices. The ventricle was filled with fluid of varying composition and constantly 
refilled by five reservoir flasks (Corning Inc., Corning, NY) situated upon the incubator’s 
top shelf, connected to the ventricle by tubing attached to ports at the base of the ventricle. 
The height differential between the incubator’s top and middle shelves, which housed the 
filling flasks and the ventricle, respectively, determined the hydrostatic potential driving fluid 
through the attached shunt systems. The ventricle’s twelfth and final bottom port was 
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connected to tubing that served as a manometer, continuously monitored to ensure 
homogeneous pressure in the physiologic ICP range, measured in cmH2O. 
This system was designed for compatibility with a range of VPS hardware. In all studies, 
valves were attached to silicone Bactiseal® proximal and distal shunt catheters (Codman by 
Integra, Plainsboro, NJ). Each proximal and distal catheter-valve interface was reinforced 
with a silk suture and the unit was submerged underwater to prevent air entry and provide 
surrounding pressure similar to a subcutaneously-implanted valve. Proximal catheters were 
passed into the ventricle to expose the hardware directly to the test fluid. The distal ends of 
the valves were connected to a distal Bactiseal® catheter and ultimately emptied into a 
collecting flask which was measured by weight with a digital scale. Placement of collecting 
flasks alternated between the incubator’s middle and bottom shelves to recreate the 
different position-dependent flow rates seen with a patient in the horizontal (supine) and 
vertical (upright) states, respectively. Every 24-hour period consisted of a 6-8 hour supine 
trial and a 12-14 hour upright trial, with distal catheter tips 2 cm and 28.5 cm below the 
height of the valves, respectively. All fluid containing flasks were opened to atmospheric 
pressure through 0.22 uM air filters (Corning Inc., Corning, NY) to provide a barrier against 
contamination while allowing pressure equilibration across the system. 
At the conclusion of each trial, the total fluid output collected from each of the six distal 





The system was designed to run a variety of fluids mimicking different physiological and 
pathological states. It was first calibrated for a month using normal saline (Hospira, Lake 
Forest, IL), followed by another month-long protein trial using saline containing 1g/L of 
Bovine Serum Albumin (BSA, Sigma Aldrich, St. Louis, MO). To further test the hardware 
under more challenging pathological conditions, human CSF with elevated protein was also 
used in several sets of trials that lasted for 30-days using new valves. CSF was collected from 
external ventricular drainage catheters in adult and pediatric patients at our institution with 
intraventricular hemorrhage after obtaining IRB approval and informed consent (IRB 
NA_00029413). All CSF samples were deidentified and combined, forming an aggregate 
with a baseline protein concentration of 1.63 g/L. BSA was added to reach a final protein 
concentration of 5 g/L. CSF was centrifuged at 2500 rpm for 20 minutes to remove blood and 
other cellular material, and the supernatant was collected and filtered with 0.22 μm low-
protein binding sterilizing filters (Corning Inc., Corning, NY, USA). Amphotericin B (final 
concentration of 2.2 mg/dL, Sigma Aldrich, St. Louis, MO), Penicillin/Streptomycin (3% v/v, 
Gibco Laboratories, Gaithersburg, MD), and Chlorhexidine dihydrochloride (Sigma Aldrich, 
St. Louis, MO) were added to this acellular, protein-enriched human CSF to minimize the 
risk of contamination. 
Samples were frozen and stored at -80° C until use after thawing. Protein concentration was 
measured at our institution laboratory core before, during, and after the end of the trial, to 
ensure that concentrations remained stable throughout. 
 
Valve Resistance Settings 
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For the initial calibration trials with normal saline and high-protein CSF, CPBVs and HBVs 
were programmed to low-resistance settings of 2 and 50, respectively. For all other trials, the 
valves were increased to settings 4 and 100. 
 
Statistical Analysis 
Hourly and average flow rates were therefore calculated along with standard deviations, and 
statistical analysis was performed using two samples t-test for independent samples and 
paired ttest for same sample measured at different conditions or time points. Repeated 
measures ANOVA was used to compare valves’ performance over time. GraphPad Prism 
Software® (Version 8.0, GraphPad Software, San Diego, CA) was used to perform statistical 
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Supplemental Table 1: Statistical analysis of variance (ANOVA) among sets of valves according to 
different positional states and fluids. 
CPBVs Supine CPBVs Upright HBVs Supine HBVs Upright 
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